LENZ Therapeutics, Inc. (LENZ) stock
Close on Nov 12, 2026Market cap $128.51MP/E –Yield –
LENZ Therapeutics, Inc. grew revenue 329.5% to $21.48M over the twelve months to Jun 30, 2026. Free cash flow was -$114.42M. At the latest close the market valued the company at $128.51M.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $128.51M
- P/E ratio
- –
- Price to sales
- 5.98
- Price to book
- 0.59
- Dividend yield
- –
- Free cash flow yield
- -89.04%
Fundamentals
- Revenue
- $21.48M
- Net income
- -$126.00M
- EPS, diluted
- -$4.08
- Free cash flow
- -$114.42M
- Book value per share
- $6.99
- Diluted shares
- 31M
Trading
- Next earnings
- Mar 23, 2027 (estimated, before the open)
- Previous close
- $4.11
- Open
- $4.10
- Day's range
- $3.94 – $4.13
- Volume
- 773,092
- Average volume (20 days)
- 1,225,151
- Index membership
- Russell 2000 (since Mar 2024), Russell 3000 (since May 2024)
- Beta (5 years)
- 1.08
- 52-week range
- $2.80 – $32.13
- RSI (14 days)
- 59.2
- Volatility (1 year)
- 84.5%
- Relative volume
- 0.65×
- WACC
- 10.3%
On 2 of our idea lists: Net-nets, More cash than they're worth
Index membership is inferred from the holdings of funds that track each index (IWM, IWV), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2021, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 12, 2026. The S&P 500 is measured by the SPY fund.
| Period | LENZ | S&P 500 | Difference | LENZ per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | +13.3% | -2.7% | +16.0 pts | ||
| 3 months | -18.8% | -1.7% | −17.1 pts | ||
| Year to date | -74.4% | +11.9% | −86.3 pts | ||
| 1 year | -84.0% | +12.0% | −95.9 pts | ||
| 3 years | -62.8% | +78.2% | −141.0 pts | -28.1% | +21.2% |
| 5 years | -92.8% | +73.2% | −166.1 pts | -41.0% | +11.6% |
Seven years at a glance
Fiscal years 2019 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases LENZ Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Results
- Results
- Results
- Results
About LENZ Therapeutics
Biological Products, (No Diagnostic Substances)
LENZ Therapeutics is a commercial pharmaceutical company that develops and commercializes innovative therapies to improve vision. The company’s primary product is VIZZ (aceclidine ophthalmic solution 1.44%), a once-daily, pupil-selective prescription eye drop formulated to restore near vision for up to ten hours in adults experiencing presbyopia. Operating primarily in the self-pay pharmaceutical market, the company provides treatments for adult patients dealing with age-related near-vision loss. Its products reach consumers through retail pharmacies, e-pharmacy partners, and partnerships with eye care professionals including optometrists and ophthalmologists.
Company profile, executives and historyLENZ Therapeutics stock: common questions
What is LENZ Therapeutics's stock price?
LENZ closed at $4.09 on Nov 12, 2026, down 0.49% on the day. Over the past 52 weeks it traded between $2.80 and $32.13.
What is LENZ Therapeutics's market cap?
LENZ Therapeutics was worth $128.51M at the close on Nov 12, 2026: the share price times the diluted shares outstanding.
What is LENZ's P/E ratio?
LENZ Therapeutics lost money over the twelve months to Jun 30, 2026 (diluted EPS -$4.08), so it has no meaningful P/E ratio.
How much revenue does LENZ Therapeutics make?
LENZ Therapeutics reported revenue of $21.48M for the twelve months to Jun 30, 2026, up 329.5% from a year earlier.
Does LENZ Therapeutics pay a dividend?
No. LENZ Therapeutics has not paid a cash dividend over the last twelve months.
When does LENZ Therapeutics report earnings next?
LENZ Therapeutics is expected to report Q4 FY2026 results on Mar 23, 2027, before the open. The date is estimated from its past reporting pattern until the company confirms it.
How has LENZ stock performed over the past year?
Including dividends, LENZ returned -84.0% over the past year, against +12.0% for the S&P 500.
How many LENZ shares are sold short?
7M shares were sold short at the latest FINRA report, 24.13% of the float, or 5.6 days of average trading volume.
Who are LENZ Therapeutics's competitors?
Companies most similar to LENZ Therapeutics by business, industry and size include ACOG, SCLX, VYGR, LCTX, OCUL.
See a number that looks wrong?